

# Global Cell Therapy Market, Price, Product & Clinical Pipeline Outlook 2024

<https://marketpublishers.com/r/G17ED30FA95EN.html>

Date: April 2018

Pages: 1200

Price: US\$ 2,400.00 (Single User License)

ID: G17ED30FA95EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Cell Therapy Market, Price, Product & Clinical Pipeline Outlook 2024” Report Highlights:

Market Analysis by Application in Various Therapeutic Areas

Comprehensive Insight On Clinical Pipeline: 664 Cell Therapies

Cell Therapy Market Opportunity More Than US\$ 25 Billion by 2024

Marketed Cell Therapies: 21

Price & Product Insight By Region/Country

Cell Therapy Clinical Pipeline Overview

Collaborations & Acquisition in the Cell Therapy Segment

Regional Analysis of the Cell Therapy Market

Cell therapy is an integral part of immunotherapy that has shown excellent therapeutic ability in several clinical indications. In recent years, studies regarding the use of cells for their therapeutic ability have gained immense popularity in the scientific and healthcare research community. The segment currently flourishes with several

techniques like CAR-T cell therapy, Stem cell therapy, and cord blood cell therapy with each of them gaining extreme popularity due to their wide application in several clinical indications such as cancer, cardiovascular disease and cancer.

The most popular and common technique of cell therapy aims at using healthy cells from a compatible donor (Allogeneic) or from the patient itself (Autogenic) and their modification to amplify their therapeutic ability. It involves complex steps like genetic screening of cell, modification of cell by genetic sequencing, their harvesting and reinfusion into the patient's body. Each of these steps plays a vital role in the therapeutic outcome, thus leading to the establishment of the cell therapy market.

Stem cell therapy is currently the dominant segment in the cell therapy market with maximum success rate reported globally. Their special ability to differentiate into any type of cell without losing their identity makes them the most promising therapeutic entities of the future. Researchers claim that stem cells are bound to revolutionize regenerative medicine with it being applied in the treatment of complex disease such as cardiovascular disease, neurodegenerative disease, inflammatory disease and cancer.

Moreover, researchers assume that modification of cell therapy techniques could result in potential cures for multiple sclerosis, diabetes, spinal cord injury, cancer, heart disease, Parkinson's disease, Alzheimer's disease, and immune system disorders. The role of cell therapy and stem cell research will also be most helpful in the therapeutic sectors of cloning and regenerative medicine

Cell therapy based products like Kymriah, Provenge and Yescarta have been well received in the market inspite of their hefty price tag; costing well over US\$ 100,000 which clearly indicates the lucrative nature of the cell therapy market.

Innovations in pharmaceutical and biotechnology research are the key driving parameters for the development of cell therapies. For instance, holoclar treatment for curing blindness, cartistem for cartilage cell regeneration and Epicel for burn wound replacement have shown excellent outcome in their initial clinical studies which could become the gold standard therapeutics of the future.

Investigators have been able to identify different stem cell sources which offers them large base for developing new therapies. Majority of the cell therapy techniques can be customized according to a patient's requirement thus making it a leading segment in personalized therapy. As a result, large numbers of stem cell therapies are entering in clinical trials across the globe. They are at different stages of development and likely to

be introduced in global market in coming years. This will help the stem cell therapy developers to generate significant revenues in coming years.

In spite of several challenges restraining the growth of the cell therapy market, experts claim the segment to be a burgeoning market of the future. This claim is supported by the fact that more than 150 companies globally have invested over US\$ 1 Billion in the fairly new industry. Active participation of countries like Japan, South Korea, China and India has made it a progressive market of the future with widely untapped potential.

Kuick Research Report on the Global cell therapy market provides a detailed insight into the current scenario of the cell therapy market worldwide. Key data like pricing of cell therapy products, cost analysis of cell therapy procedures, adoption rate, current market trends and recent developments that might impact the cell therapy market are also highlighted in the report. Further, extensive analysis using data from primary and secondary source has been used for the effective forecast and future projections regarding the cell therapy market.

## Contents

### **1. PROLOGUE TO CELL THERAPY**

- 1.1 An Overview to Cells & Their Therapeutic Ability
- 1.2 Unique Features of Cellular Therapeutics
  - 1.2.1 Stem Cells – Key Agents of Cellular Based Therapeutics
  - 1.2.2 Key Advantages of Cell Therapy over Other Existing Therapeutics

### **2. MECHANISM OF CELL THERAPY TREATMENT**

- 2.1 Principle of Cell Therapy
  - 2.1.1 Cell Therapy & the Immune Response
  - 2.1.2 Mechanism of Regenerative Cell Therapy
- 2.2 Role of Surface Markers & Their Targeting
  - 2.2.1 Targeting the Signal Cascades
  - 2.2.2 Targeting the Microenvironment
- 2.3 Allogeneic Stem Cell Therapy
- 2.4 Autologous Stem Cell Therapy

### **3. STEM CELLS - THEIR APPLICATION & CONTRIBUTION IN THE ESTABLISHMENT OF CELL THERAPY MARKET**

- 3.1 Origin of Stem Cells
  - 3.1.1 Embryonic Stem Cells
  - 3.1.2 Adult Stem Cells
  - 3.1.3 Induced Pluripotent Stem Cells (iPSCs)
- 3.2 Exploring Stem Cell's Ability to Differentiate
  - 3.2.1 Totipotent Stem Cells
  - 3.2.2 Pluripotent Stem Cells
  - 3.2.3 Multipotent Stem Cells
  - 3.2.4 Unipotent Stem Cells

### **4. CELL THERAPY MARKET ANALYSIS BY APPLICATION IN VARIOUS THERAPEUTIC AREAS**

- 4.1 Cell Therapy for Cardiovascular Disease
  - 4.1.1 Myocardial Infarction
  - 4.1.2 Heart Failure

#### 4.2 Cell Therapy for Neurological Disorders

4.2.1 Parkinson's Diseases

4.2.2 Alzheimer's Diseases

4.2.3 Huntington's Diseases

#### 4.3 Cell Therapy for Inflammatory Diseases

4.3.1 Asthma

4.3.2 Arthritis

#### 4.3 Cell Therapy for Diabetes

4.3.3 Type 1 diabetes

4.3.4 Type 2 diabetes

#### 4.4 Cell Therapy for Cancer

4.4.1 Stem Cells & Their Therapeutic Role in Cancer

4.4.2 Role of Surface Markers & Their Targeting

4.4.3 Targeting the Signal Cascades

4.4.4 Targeting the Microenvironment

### **5. PRODUCT & PRICE ANALYSIS OF CELL THERAPY APPROVED IN US**

5.1 Apligraf & Dermagraft

5.2 Carticel

5.3 ChondroCelect

5.4 Epicel

5.5 Holoclar

5.6 Kymriah

5.7 Provenge

5.8 Yescarta

### **6. PRODUCT & PRICE ANALYSIS OF CELL THERAPY PRODUCTS APPROVED IN EUROPE**

6.1 Spherox

6.2 Strimvelis

### **7. PRODUCT & PRICE ANALYSIS OF CELL THERAPY APPROVED IN SOUTH KOREA**

7.1 Cartistem

7.2 Cupistem

7.3 Hearticellgram

## **8. PRODUCT & PRICE ANALYSIS OF CELL THERAPY APPROVED IN JAPAN**

8.1 HeartSheet

8.2 Temcell

## **9. CURRENT STATUS OF THE GLOBAL CELL THERAPY MARKET**

9.1 Overview of the Global Cell Therapy Market

9.2 Industrial Insight into the Cell Therapy Market – Key Players & Their Contribution

9.3 Cell Therapy Clinical Pipeline Overview

9.4 Investments in the Cell Therapy Market

## **10. GLOBAL CELL THERAPY MARKET TRENDS**

10.1 Cell Therapy Enhancing the Effect of Existing Therapeutic Methods

10.2 Cell Therapy Market More Oriented Towards Immune Cells

10.3 Involvement of Both Academia & Industries to Enhance Progress of Cell Therapy Studies

10.4 Impact of Cell Therapy on the Drug Delivery Market

10.4.1 Direct Delivery Methods

10.4.2 Indirect Delivery Method

## **11. COLLABORATIONS & ACQUISITION IN THE CELL THERAPY SEGMENT**

11.1 Collaborations

11.2 Acquisition

## **12. REGIONAL ANALYSIS OF THE CELL THERAPY MARKET**

12.1 North America

12.2 Europe

12.3 Asia

12.3.1 China

12.3.2 Japan

12.3.3 South Korea

12.3.4 India

12.4 Rest of the World

12.4.1 Africa

12.4.2 Middle East

12.4.3 South America

### **13. GLOBAL CELL THERAPY MARKET DYNAMICS**

13.1 Growth Promoting Parameters of the Cell Therapy Market

13.2 Commercial Challenges of the Cell Therapy Market

### **14. FUTURE PROSPECTUS & SCOPE OF THE CELL THERAPY MARKET**

### **15. GLOBAL CELL THERAPY CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

15.1 Unknown

15.2 Research

15.3 Preclinical

15.4 Clinical

15.5 Phase-0

15.6 Phase-I

15.7 Phase-I/II

15.8 Phase-II

15.9 Phase-II/III

15.10 Phase-III

15.11 Preregistration

15.12 Registered

### **16. MARKETED CELL THERAPY CLINICAL INSIGHT**

16.1 Immuncell-LC

16.2 Adipocell (Anterogen)

16.3 Provenge

16.4 CureXcell

16.5 Holoclar

16.6 MACI

16.7 Carticel

16.8 MyoCell

16.9 Laviv

16.10 Prochymal

16.11 Grafix

- 16.12 Gintuit
- 16.13 Autologous Mesenchymal Stem Cell Therapy – Pharmicell
- 16.14 Cartistem
- 16.15 CHONDRON
- 16.16 BioCart
- 16.17 NuCel
- 16.18 Dendritic Cell-Activated Cytokine-Induced Killer Cells
- 16.19 Chondrotransplant DISC
- 16.20 Urocell
- 16.21 CellSpray

## **17. COMPETITIVE LANDSCAPE**

- 17.1 AlloCure
- 17.2 Arteriocyte Medical Systems
- 17.3 Athersys Inc.
- 17.4 Baxter Healthcare Corporation
- 17.5 Bone Therapeutics
- 17.6 Celgene Corporation
- 17.7 Cell Medica
- 17.8 Cellerant Therapeutics
- 17.9 FibrocellScience
- 17.10 Forticell Bioscience
- 17.11 Genzyme Corporation
- 17.12 Green Cross Cell
- 17.13 Histogenics Corporation
- 17.14 InnovacellBiotechnologie AG
- 17.15 Intrexon Corporation
- 17.16 Intercytex
- 17.17 ISTO Technologies
- 17.18 Macrocare
- 17.19 Mesoblast
- 17.20 Molmed
- 17.21 Nuo Therapeutics Inc
- 17.22 OmniCyte
- 17.23 Opexa Therapeutics
- 17.24 Organogenesis
- 17.25 Pharmicell
- 17.26 TCA Cellular Therapy

17.27 Stem Cell Inc.

17.28 Teva Pharmaceuticals

17.29 Tigenix

17.30 Vericel Corporation

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Basic Overview of Cell Therapy
- Figure 1-2: Historical Insight into Cell Therapy
- Figure 1-3: Key Goals of using Cell Therapy
- Figure 2-1: Mechanism of Paracrine Signaling
- Figure 2-2: Demonstration of the Endocrine Signaling
- Figure 2-3: Illustration of the Autocrine Signaling
- Figure 2-4: Paracrine Signaling in Heart Repair
- Figure 2-5: Common Sources of Cells in Cell Therapy
- Figure 2-6: Requirements of an Ideal Cell Donor in Cell Therapy
- Figure 2-7: Steps in Allogeneic Stem Cell Therapy
- Figure 2-8: Steps in Autologous Stem Cell Therapy
- Figure 3-1: Application of Cell Therapy in Various Clinical Indications
- Figure 3-2: Global - Cell Therapy Type by Donor Cell Source (%).2018
- Figure 3-3: Global - Stem Cell v/s Non Stem Cell Therapy Studies (%), 2018
- Figure 3-4: Type of Stem Cells on the Basis of Origin
- Figure 3-5: Global - Cell Therapy Product Source (%), 2018
- Figure 3-6: Type of Stem Cells & Their Ability to Differentiate
- Figure 3-7: Global - Type of Immune Cells Used in Cell Therapy (%), 2018
- Figure 4-1: Global - Mortality Caused by Non Communicable Disease (%), 2018
- Figure 4-2: Cell Therapy – Clinical Trials by Indication (%), 2018
- Figure 4-3: Cell Therapy for Cardiovascular Disease
- Figure 4-4: Overview of Stem Cell Therapy in Cardiovascular Disease
- Figure 4-5: Cell Therapy in Neurological Disorders
- Figure 4-6: Cell Therapy in Treatment of Alzheimer's disease
- Figure 4-7: Cell Therapy in Diabetes
- Figure 5-1: Apligraf - Cost per Use (US\$/Patient), 2018
- Figure 5-2: Carticel - Price Analysis (US\$/Patient), 2018
- Figure 5-3: ChondroCelect - Price Analysis (US\$/Patient), 2018
- Figure 5-4: Epicel - Price Analysis per 1% Total Body Surface Area (US\$/Patient), 2018
- Figure 5-5: Kymriah - Therapy Price Analysis (US\$/Year), 2018
- Figure 5-6: Provenge - Price Analysis (US\$/Year), 2018
- Figure 5-7: Yescarta - Price Analysis (US\$), 2018
- Figure 6-1: Spherox - Price Analysis (US\$/Patient), 2018
- Figure 6-2: Strimvelis - Price Analysis (US\$ & Euro), 2018
- Figure 7-1: Cartistem - Price Analysis (US\$/Dose), 2018

Figure 7-2: Hearticellgram - Price Analysis (US\$/Patient), 2018  
Figure 8-1: HeartSheet - Treatment Cost Analysis (US\$/ Administration), 2018  
Figure 8-2: Temcell - Price Analysis (US\$/72 Million Cells), 2018  
Figure 9-1: Global - Cell Therapy Clinical Pipeline by Phase (%), 2018 till 2024  
Figure 9-2: Global - Cell Therapy Clinical Pipeline by Phase (Number), 2018 till 2024  
Figure 9-3: Global - Cell Therapy Clinical Pipeline by Discontinued Trials(%),2018 till 2024  
Figure 9-4: Global - Cell Therapy Clinical Pipeline by Discontinued Trials (Number), 2018 till 2024  
Figure 10-1: Global - Preference of Cell Type in Cell Therapy (%), 2018  
Figure 10-2: Cell Therapy - Funding in Industry & Academia (%), 2018  
Figure 12-1: Cell Therapy - Trials Conducted by Region (%), 2018  
Figure 12-2: Europe – Cell Therapy Clinical Trial Analysis by Region (%), 2018  
Figure 12-3: Asia – Cell Therapy Clinical Trial by Region (%), 2018  
Figure 12-4: Cell Therapy-Comparative Cost Analysis by Region (US\$), 2018  
Figure 12-5: Rest of the World – Cell Therapy Clinical Trial by Region (%), 2018  
Figure 13-1: Global – Key Factors Driving the Cell Therapy Market  
Figure 13-2: Global - Cell Therapy Market Challenges  
Figure 14-1: Future Objectives of the Cell Therapy market  
Figure 14-2: Global - Cell Therapy Market Opportunity (US\$ Billion), 2018 -2024  
Figure 14-3: Key Developments Impacting the Future Cell Therapy Market  
Figure 17-1: Arteriocyte Medical Systems Clinical Pipeline  
Figure 17-2: Bone Therapeutics Clinical Pipeline  
Figure 17-3: Celgene Clinical Pipeline  
Figure 17-4: Cellerant Therapeutics Clinical Pipeline  
Figure 17-5: Fibrocell Science Clinical Pipeline  
Figure 17-6: Genzyme Clinical Pipeline  
Figure 17-7: Intrexon Clinical Pipeline  
Figure 17-8: ISTO Clinical Pipeline  
Figure 17-9: Mesoblast Clinical Pipeline  
Figure 17-10: Molmed Clinical Pipeline  
Figure 17-11: Pharmicell Clinical Pipeline  
Figure 17-12: Tigenix Clinical Pipeline  
Figure 17-13: Vericel Corporation Clinical Pipeline

## **COMPANIES**

AlloCure, Arteriocyte Medical Systems, Athersys Inc., Baxter Healthcare Corporation, Bone Therapeutics, Celgene Corporation, Cell Medica, Cellerant Therapeutics,

FibrocellScinence, Forticell Bioscience, Genzyme Corporation, Green Cross Cell, Histogenics Corporation, InnovacellBiotechnologie AG, Intrexon Corporation, Intercytex, ISTO Technologies, Macrocare, Mesoblast, Molmed, Nuo Therapeutics Inc, OmniCyte, Opexa Therapeutics, Organogenesis, Pharmicell, TCA Cellular Therapy, Stem Cell Inc., Teva Pharmaceuticals, Tigenix, Vericel Corporation

## I would like to order

Product name: Global Cell Therapy Market, Price, Product & Clinical Pipeline Outlook 2024

Product link: <https://marketpublishers.com/r/G17ED30FA95EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G17ED30FA95EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970